MX2019013259A - Vectores de neoantigeno de alfavirus. - Google Patents

Vectores de neoantigeno de alfavirus.

Info

Publication number
MX2019013259A
MX2019013259A MX2019013259A MX2019013259A MX2019013259A MX 2019013259 A MX2019013259 A MX 2019013259A MX 2019013259 A MX2019013259 A MX 2019013259A MX 2019013259 A MX2019013259 A MX 2019013259A MX 2019013259 A MX2019013259 A MX 2019013259A
Authority
MX
Mexico
Prior art keywords
vectors
neoantigen
alphavirus
disclosed
vaccines
Prior art date
Application number
MX2019013259A
Other languages
English (en)
Inventor
Blair Wade
Gitlin Leonid
Jooss Karin
Daniel Scallan Ciaran
Rachel Rappaport Amy
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of MX2019013259A publication Critical patent/MX2019013259A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

En la presente, se describen vectores de alfavirus que incluyen secuencias de ácidos nucleicos que codifican neoantígenos derivadas de un tumor de un sujeto. También se describen nucleótidos, células y métodos asociados a los vectores, incluido su uso como vacunas.
MX2019013259A 2017-05-08 2018-05-08 Vectores de neoantigeno de alfavirus. MX2019013259A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762503283P 2017-05-08 2017-05-08
US201762523201P 2017-06-21 2017-06-21
US201762590163P 2017-11-22 2017-11-22
PCT/US2018/031696 WO2018208856A1 (en) 2017-05-08 2018-05-08 Alphavirus neoantigen vectors

Publications (1)

Publication Number Publication Date
MX2019013259A true MX2019013259A (es) 2020-01-13

Family

ID=64105513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013259A MX2019013259A (es) 2017-05-08 2018-05-08 Vectores de neoantigeno de alfavirus.

Country Status (16)

Country Link
US (3) US11504421B2 (es)
EP (1) EP3634449A4 (es)
JP (2) JP2020518648A (es)
KR (1) KR20200003390A (es)
CN (1) CN110612116A (es)
AU (2) AU2018266705B2 (es)
BR (1) BR112019023477A2 (es)
CA (1) CA3062591A1 (es)
CO (1) CO2019013609A2 (es)
MX (1) MX2019013259A (es)
PE (1) PE20191842A1 (es)
PH (1) PH12019502518A1 (es)
SG (1) SG11201910101SA (es)
TW (2) TW202333779A (es)
WO (1) WO2018208856A1 (es)
ZA (1) ZA201907461B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545810A (zh) * 2016-11-23 2019-12-06 磨石肿瘤生物技术公司 新抗原的病毒递送
CA3053133A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
CN110612116A (zh) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 甲病毒新抗原载体
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
WO2020121273A1 (en) * 2018-12-14 2020-06-18 Glaxosmithkline Biologicals Sa Heterologous prime boost vaccine compositions and methods
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
SG11202113187WA (en) * 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
JP2022536695A (ja) * 2019-06-12 2022-08-18 ビオンテック ユーエス インコーポレイテッド 新抗原組成物およびその使用
AU2020298552A1 (en) * 2019-07-02 2022-03-03 Gritstone Bio, Inc. HIV antigens and MHC complexes
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
CN110515301B (zh) * 2019-08-06 2021-06-08 大连理工大学 一种结合dmpc的改进的admm算法
AU2020328511A1 (en) 2019-08-09 2022-03-03 Nutcracker Therapeutics, Inc. Methods and apparatuses for manufacturing for removing material from a therapeutic composition
EP4125973A4 (en) * 2019-11-04 2024-03-13 Gritstone Bio Inc NEOANTIGEN VACCINE THERAPY
AU2021233816A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
CN115942942A (zh) * 2020-04-03 2023-04-07 磨石生物公司 感染性疾病抗原和疫苗
CN111951887A (zh) * 2020-07-27 2020-11-17 深圳市新合生物医疗科技有限公司 基于深度学习的白细胞抗原与多肽结合亲和力预测方法
KR20230046313A (ko) * 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
CN114438128A (zh) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 一种增强型溶瘤腺病毒及其应用
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US20220194999A1 (en) * 2020-12-23 2022-06-23 Janssen Biotech, Inc. Neoantigen Peptide Mimics
CN112553232B (zh) * 2020-12-29 2022-10-21 中国科学院武汉病毒研究所 多功能自组装纳米颗粒的可控生物合成方法
CN117279660A (zh) * 2021-01-19 2023-12-22 磨石生物公司 经修饰的甲病毒载体
EP4308136A1 (en) 2021-03-19 2024-01-24 Tiba Biotech LLC Artificial alphavirus-derived rna replicon expression systems
CA3216276A1 (en) 2021-04-29 2022-11-03 Yardena Samuels T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
CN113517030B (zh) * 2021-07-19 2022-09-20 中国人民解放军国防科技大学 基于病毒传播网络的基因序列表示学习方法
EP4373852A1 (en) * 2021-07-22 2024-05-29 The Government of the United States of America as represented by the Secretary of the Navy Single domain antibodies that bind and neutralize venezuelan equine encephalitis virus
WO2023172633A1 (en) * 2022-03-08 2023-09-14 Avalo, Inc. System and method for genomic association
WO2023183827A2 (en) * 2022-03-21 2023-09-28 Gritstone Bio, Inc. Low-dose neoantigen vaccine therapy
WO2024026274A2 (en) * 2022-07-26 2024-02-01 Yale University Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20050271676A1 (en) 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0982405B1 (en) 1993-09-15 2009-08-26 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
AU678867B2 (en) 1993-11-09 1997-06-12 Medical College Of Ohio, The Stable cell lines capable of expressing the adeno-associated virus replication gene
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996013597A2 (en) 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5552350A (en) 1994-12-12 1996-09-03 Ceramco Inc. Low-fusing temperature porcelain
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5851796A (en) 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
UY24367A1 (es) 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
JP2001503735A (ja) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
EP1000628A1 (en) 1998-09-28 2000-05-17 Fondation Mondiale Recherche et Prevention SIDA Use of antigenic complexes of HIV envelope and HLA class I antigens as HIV vaccine
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
AU771774B2 (en) 1998-12-07 2004-04-01 U.S. Medical Research Institute Of Infectious Diseases Live attenuated Venezuelan equine encephalitis vaccine
WO2000047229A2 (en) 1999-02-11 2000-08-17 Genzyme Corporation Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
US7262049B2 (en) 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
AU4077100A (en) 1999-04-08 2000-11-14 Chiron Corporation Enhancement of the immune response for vaccine and gene therapy applications
DK1175497T3 (da) 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
JP2003521245A (ja) 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
US20040248113A1 (en) 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2397998A1 (en) 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
EP2311950A1 (en) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
AU2001252945A1 (en) 2000-03-24 2001-10-08 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20040115625A1 (en) 2000-10-02 2004-06-17 Reinhard Ebner Cancer gene determination and therapeutic screening using signature gene sets
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002027007A2 (en) 2000-09-25 2002-04-04 Regents Of The University Of Michigan Production of viral vectors
US20020137081A1 (en) 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
US7557200B2 (en) 2001-02-01 2009-07-07 Johns Hopkins University Superior molecular vaccine based on self-replicating RNA, suicidal DNA or naked DNA vector, that links antigen with polypeptide that promotes antigen presentation
EP2305299B1 (en) 2001-05-31 2017-03-01 GlaxoSmithKline Biologicals SA Chimeric alphavirus replicon particles
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
IL164802A0 (en) 2002-04-25 2005-12-18 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
IL164803A0 (en) 2002-04-25 2005-12-18 Crucell Holland Bv Means and methods for the production of adenovirusvectors
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
EP1594447A2 (en) 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1571909A4 (en) 2002-10-03 2009-11-11 Idm Pharma Inc OPTIMIZED CONSTRUCTIONS WITH SEVERAL EPITOPES AND USES THEREOF
EP1590451B1 (en) 2002-12-13 2015-09-16 Alphavax, Inc. Alphavirus particles and methods for preparation
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
GB2398300A (en) 2003-02-17 2004-08-18 Isis Innovation Method and compositions for boosting immune response
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US7541038B2 (en) 2003-06-05 2009-06-02 Wyeth Holdings Corporation Fusogenic, self-propagating blebs as immunogenic compositions
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
CN102719478A (zh) 2004-01-23 2012-10-10 P.安杰莱蒂分子生物学研究所 黑猩猩腺病毒疫苗载运体
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
EP1742668B1 (en) 2004-04-28 2011-02-09 The Trustees of The University of Pennsylvania Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
ES2442225T3 (es) 2004-04-28 2014-02-10 The Trustees Of The University Of Pennsylvania Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
CA2567047C (en) 2004-05-25 2015-06-30 Zequn Tang Alphavirus replicon packaging constructs
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
CA2582426A1 (en) 2004-10-04 2006-04-13 Biovaxim Limited Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
FR2882557A1 (fr) 2005-02-25 2006-09-01 Centre Nat Rech Scient Epitopes de vih et composition pharmaceutique les contenant
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
EP3002330A1 (en) * 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Gene vector
TR201909609T4 (tr) 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
BRPI0708332A2 (pt) 2006-02-27 2011-05-24 Univ Texas flavivìrus pseudoinfeccioso e uso deste
NZ575901A (en) 2006-09-12 2012-04-27 Alphavax Inc Alphavirus replicon particles matched to protein antigens as immunological adjuvants
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
EP2167137B1 (en) 2007-05-31 2013-10-16 GENimmune N.V. Hpv polyepitope constructs and uses thereof
AU2008266807B2 (en) 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US20100015179A1 (en) 2007-08-16 2010-01-21 Frolov Ilya V Attenuation of encephalitogenic alphavirus and uses thereof
WO2009034190A2 (en) 2007-09-14 2009-03-19 Genimmune N.V. Affinity tag
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
CA2705787A1 (en) 2007-11-26 2009-06-25 Novartis Ag Methods of generating alphavirus particles
US20110091496A1 (en) 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
US20090253184A1 (en) 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
SG187513A1 (en) 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
EP2271754A4 (en) 2008-03-28 2013-01-16 Virxsys Corp IMMUNOGENIC VECTORS BASED ON LENTIVIRUS
WO2009146902A1 (en) 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
WO2010005704A2 (en) * 2008-06-13 2010-01-14 New York University Novel helper plasmid, defective sindbis viral vectors and methods of use thereof
ES2902787T3 (es) 2008-07-17 2022-03-29 Medigen Inc Vacunas de ADNi y procedimientos para utilizar las mismas
SI2172211T1 (sl) * 2008-10-01 2015-03-31 Immatics Biotechnologies Gmbh Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US8807362B2 (en) 2008-10-17 2014-08-19 Jeong-min Lee Bottle cap
CN107574156A (zh) 2008-11-26 2018-01-12 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
EP2370584B1 (en) 2008-12-01 2014-11-05 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP3385387B1 (en) 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CN101579528B (zh) 2009-06-24 2011-06-29 中国人民解放军军事医学科学院军事兽医研究所 一种hiv复合多表位dna疫苗及其应用
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
DK2519266T3 (da) 2009-12-31 2017-11-06 Medigen Inc Infektiøse DNA vacciner mod Chikungunya virus
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
ES2564841T3 (es) 2010-05-14 2016-03-29 The General Hospital Corporation Composiciones y métodos para identificar neoantígenos específicos de un tumor
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
BR112013000392B8 (pt) 2010-07-06 2022-10-04 Novartis Ag Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
LT4066855T (lt) 2010-08-31 2023-03-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr tiekimui
PT4008357T (pt) 2010-08-31 2023-01-11 Glaxosmithkline Biologicals Sa Lipossomas pequenos para entrega de arn que codifica um imunogénio
BR112013016708B1 (pt) 2010-12-30 2021-08-17 Foundation Medicine, Inc Otimização de análise multigene de amostras de tumor
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
RS62497B1 (sr) 2011-05-24 2021-11-30 BioNTech SE Individualizovane vakcine protiv kancera
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
EP2729126B1 (en) 2011-07-06 2020-12-23 GlaxoSmithKline Biologicals SA Liposomes having useful n:p ratio for delivery of rna molecules
KR102067760B1 (ko) 2011-08-16 2020-01-17 삼성전자주식회사 세포 내 전달용 단백질 복합체 및 그의 용도
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
JP6305925B2 (ja) 2011-10-11 2018-04-18 ノバルティス アーゲー 組換え自己複製ポリシストロニックｒｎａ分子
RU2705301C2 (ru) 2012-02-16 2019-11-06 Влп Терапьютикс, Ллк Композиция вирусоподобных частиц
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
SG11201407343XA (en) 2012-05-18 2014-12-30 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014006146A1 (en) 2012-07-04 2014-01-09 Sirion Biotech Gmbh Means and methods to increase adenovirus production
JP2015522580A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
GB201220119D0 (en) 2012-11-08 2012-12-26 Univ Cork Vector
US9402888B2 (en) 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
CA2908434C (en) 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
JP6734651B2 (ja) 2013-06-03 2020-08-05 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ マラリアワクチン
KR102006527B1 (ko) 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
NZ721105A (en) 2013-12-06 2022-04-29 Broad Inst Inc Formulations for neoplasia vaccines
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
BR112017004202A2 (pt) 2014-09-03 2019-09-03 Bavarian Nordic As composições para intensificar respostas imunes e seus usos
CA2968399A1 (en) 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
EP3250233A4 (en) 2015-01-29 2018-07-25 Agency for Science, Technology and Research Nanocapsules carrying chikungunya-associated peptides
EP3253795B1 (en) 2015-02-06 2019-04-17 Navigo Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
WO2016154047A2 (en) 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
JP6944877B2 (ja) 2015-03-23 2021-10-06 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
SI3954225T1 (sl) 2015-09-21 2024-03-29 Trilink Biotechnologies, Llc Iniciacijski omejeni oligonukleotidni primer za sintezo 5'-omejenih RNK
KR20180083327A (ko) 2015-10-12 2018-07-20 난토믹스, 엘엘씨 바이러스성 암 네오에피토프를 위한 조성물 및 방법
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
MX2018010362A (es) 2016-02-29 2019-03-28 Found Medicine Inc Metodos y sistemas para evaluar carga mutacional de tumores.
EP3423078A4 (en) 2016-03-03 2019-11-06 Cue Biopharma, Inc. T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF
IL299926A (en) 2016-03-31 2023-03-01 Biontech Us Inc Neoantigens and methods for using them
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
JP7033549B2 (ja) 2016-05-04 2022-03-10 フレッド ハッチンソン キャンサー リサーチ センター 細胞に基づくネオ抗原ワクチンおよびその使用
US10967057B2 (en) 2016-06-02 2021-04-06 Glaxosmithkline Biologicals S.A. Zika viral antigen constructs
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
CN107698593A (zh) 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
MA45999A (fr) 2016-08-22 2019-06-26 Arbutus Biopharma Corp Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
CN110545810A (zh) 2016-11-23 2019-12-06 磨石肿瘤生物技术公司 新抗原的病毒递送
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201621732D0 (en) 2016-12-20 2017-02-01 Agricultural Research Council A multi-epitope dna vaccine for heartwater
EP3558271A4 (en) 2016-12-21 2020-07-22 Arbutus Biopharma Corporation METHOD FOR IMPROVING INFUSION REACTIONS
CN111093691A (zh) 2017-04-03 2020-05-01 内恩疗法公司 蛋白质抗原及其用途
CN110612116A (zh) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 甲病毒新抗原载体
WO2018227030A1 (en) 2017-06-09 2018-12-13 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
AR112166A1 (es) 2017-06-16 2019-09-25 Arbutus Biopharma Corp Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
US11674962B2 (en) 2017-07-21 2023-06-13 Genentech, Inc. Therapeutic and diagnostic methods for cancer
BR112020002555A2 (pt) 2017-08-07 2020-08-11 The Johns Hopkins University métodos e materiais para avaliar e tratar câncer
EP3704268A4 (en) 2017-11-03 2021-08-11 Guardant Health, Inc. NORMALIZATION OF A TUMOR MUTATION LOAD
JP2021516962A (ja) 2018-03-06 2021-07-15 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ バリアント検出の改善
JP2021525076A (ja) 2018-05-23 2021-09-24 グリットストーン バイオ インコーポレイテッド 共有抗原
AU2019275070A1 (en) 2018-05-23 2021-01-14 Gritstone Bio, Inc. Immune checkpoint inhibitor co-expression vectors
AU2019374874A1 (en) 2018-11-07 2021-06-10 Gritstone Bio, Inc. Alphavirus neoantigen vectors and interferon inhibitors
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
AU2020298552A1 (en) 2019-07-02 2022-03-03 Gritstone Bio, Inc. HIV antigens and MHC complexes
EP4125973A4 (en) 2019-11-04 2024-03-13 Gritstone Bio Inc NEOANTIGEN VACCINE THERAPY
WO2021119545A1 (en) 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
WO2021142437A1 (en) 2020-01-10 2021-07-15 Gritstone Bio, Inc. Cell-free dna monitoring
CN115803049A (zh) 2020-04-21 2023-03-14 磨石生物公司 抗原编码盒
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트

Also Published As

Publication number Publication date
US20200197500A1 (en) 2020-06-25
US11510973B2 (en) 2022-11-29
WO2018208856A1 (en) 2018-11-15
BR112019023477A2 (pt) 2020-06-30
PE20191842A1 (es) 2019-12-31
PH12019502518A1 (en) 2020-07-20
KR20200003390A (ko) 2020-01-09
JP2020518648A (ja) 2020-06-25
AU2023202423A1 (en) 2023-05-11
TW201907937A (zh) 2019-03-01
ZA201907461B (en) 2023-04-26
TW202333779A (zh) 2023-09-01
US20220226453A1 (en) 2022-07-21
AU2018266705B2 (en) 2023-05-04
RU2019138741A3 (es) 2021-09-23
US11504421B2 (en) 2022-11-22
CN110612116A (zh) 2019-12-24
AU2018266705A1 (en) 2020-01-02
RU2019138741A (ru) 2021-06-09
JP2023123766A (ja) 2023-09-05
CO2019013609A2 (es) 2020-04-01
EP3634449A4 (en) 2021-03-17
CA3062591A1 (en) 2018-11-15
US20240024445A1 (en) 2024-01-25
EP3634449A1 (en) 2020-04-15
SG11201910101SA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12019502518A1 (en) Alphavirus neoantigen vectors
PH12019501130A1 (en) Viral delivery of neoantigens
GB2573663A (en) Viral methods of making genetically modified cells
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
GB2557123A (en) Modified cells and methods of therapy
MX2017009506A (es) Polinucleotidos de acido desoxirribonucleico (adn)/acido ribonucleico (arn) hibridos de repeticiones palindromicas cortas agrupadas regularmente separadas (crispr) y sus metodos de uso.
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2017007677A (es) Inmunomoduladores.
EP3741849A3 (en) Protease variants and polynucleotides encoding same
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
MX2017004542A (es) Inmunomoduladores.
JOP20190161A1 (ar) مستشعرات جلوكوز بطيف قريب من الأشعة تحت الحمراء
MY184870A (en) Immunomodulators
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
TW201613613A (en) Substituted nucleosides, nucleotides and analogs thereof
MX2018008051A (es) Variantes de beta-glucanasa y polinucleotidos que las codifican.
WO2019226939A8 (en) Immune checkpoint inhibitor co-expression vectors
WO2016062875A3 (en) Glucoamylase variants and polynucleotides encoding same
EP3998341A3 (en) Adenoviral vectors
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
SG11201705820UA (en) Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
MX2022001801A (es) Secuencias recombinantes de cromosoma b de maiz y sus usos.
MX2018005872A (es) Profarmacos de acido nucleico.
HK1246215A1 (zh) 去細胞角膜及其製備方法和用途